In a phase I/II trial, the combination of azacitidine, venetoclax, and gilteritinib was evaluated in R/R AML, ND AML unfit for IC, or high risk CMML/MDS FLT3-ITD or TKD-mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.